Search for most updated materials ↑
|front |1 |2 |3 |4 |5 |6 |7 |8 |9 |review|
Clinical outcomes and immune responses
•Chroquine, Lopinavir/ritonavir, vaccines instituting etc will need safety guarantees before instituting to the public.(Phase one thru three trials) in developed countries.
•Immune responses i.e Innate and adaptive responses need further studies in the context of a HIV burden in Southern Africa including efficacy of neutralizing antibodies and re-emergence of antibodies after symptomatic patients recover.
•Clinical outcomes of severely affected individuals in Sub Saharan Africa have not been well documented, as opposed to the Wuhan, China experience/cohort that started in December 2019 and has been published in various peer reviewed journal's.